Results 1 to 10 of about 292,142 (337)

Interim opioid agonist treatment for opioid addiction: a systematic review [PDF]

Harm Reduction Journal, 2022
Background Opioid use disorder is a public health problem and treatment variability, coverage and accessibility poses some challenges. The study’s objective is to review the impact of interim opioid agonist treatment (OAT), a short-term approach for ...
Laura Samsó Jofra, Teresa Puig, Ivan Solà, Joan Trujols   +3 more
doaj   +7 more sources

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes

Addiction Science & Clinical Practice, 2022
Background Virtually delivered healthcare (telehealth, telemedicine) has the potential to reduce gaps in access to opioid agonist therapy (OAT). Barriers to accessing OAT such as lack of transportation, in-person induction requirements, employment ...
Nathaniel Day, Maureen Wass, Kelly Smith
doaj   +4 more sources

Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt.

JAMA Netw Open
ImportanceAt the onset of the COVID-19 pandemic, the government of British Columbia, Canada, released clinical guidance to support physicians and nurse practitioners in prescribing pharmaceutical alternatives to the toxic drug supply. These alternatives included opioids and other medications under the risk mitigation guidance (RMG), a limited form of ...
Min JE, Guerra-Alejos BC, Yan R, Palis H, Barker B, Urbanoski K, Pauly B, Slaunwhite A, Bach P, Ranger C, Heaslip A, Nosyk B.   +11 more
europepmc   +4 more sources

Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study

Substance Abuse Treatment, Prevention, and Policy, 2022
Background Concurrent opioid and stimulant use is on the rise in North America. This increasing trend of use has been observed in the general population, and among people released from prison in British Columbia (BC), who face an elevated risk of ...
Heather Palis, Bin Zhao, Pam Young, Mo Korchinski, Leigh Greiner, Tonia Nicholls, Amanda Slaunwhite   +6 more
doaj   +2 more sources

Opioid agonist treatment for people who are dependent on pharmaceutical opioids

Cochrane Database of Systematic Reviews, 2022
There are ongoing concerns regarding pharmaceutical opioid-related harms, including overdose and dependence, with an associated increase in treatment demand. People dependent on pharmaceutical opioids appear to differ in important ways from people who use heroin, yet most opioid agonist treatment research has been conducted in people who use heroin ...
Suzanne, Nielsen, Wai Chung, Tse, Briony, Larance   +2 more
openaire   +3 more sources

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report

Harm Reduction Journal, 2021
Background For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine ...
Heather Palis, Scott MacDonald, Jennifer Jun, Eugenia Oviedo-Joekes   +3 more
doaj   +2 more sources

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis

BMJ Open, 2021
Objective To describe opioid agonist treatment prescribing rates in provincial prisons and compare with community prescribing rates.Design We used quarterly, cross-sectional data on the number and proportion of people prescribed opioid agonist treatment ...
Fiona Kouyoumdjian, Lori Kiefer, Susan Bondy, Claire Bodkin, Leonora Regenstreif   +4 more
doaj   +2 more sources

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data

Harm Reduction Journal, 2020
Background Due to the high prevalence of mental disorders among people with opioid use disorder, the objective of this study was to determine the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention ...
Kristen A. Morin, Joseph K. Eibl, Graham Gauthier, Brian Rush, Christopher Mushquash, Nancy E. Lightfoot, David C. Marsh   +6 more
doaj   +2 more sources

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)

Substance Abuse Treatment, Prevention, and Policy
Background Across different types of oral Opioid Agonist Treatment for people with Opioid Use Disorder, receiving a dose that meets their needs is associated with better outcomes. Evidence also shows patients are more likely to receive an “adequate dose”
Scott Beaumont, Tianna Magel, Scott MacDonald, Scott Harrison, Martin Schechter, Eugenia Oviedo-Joekes   +5 more
doaj   +2 more sources

In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice [PDF]

Frontiers in Pharmacology, 2018
Pain, particularly chronic pain, is still an unsolved medical condition. Central goals in pain control are to provide analgesia of adequate efficacy and to reduce complications associated with the currently available drugs.
Roberta Lattanzi, Silvia Rief, Helmut Schmidhammer, Lucia Negri, Mariana Spetea   +4 more
doaj   +4 more sources